CXCL5 and neoplasm: CB-839 and 5-FU/Capecitabine (oral form of 5-FU) combination treatment upregulate IL-8/CXCL5 (human/mice), leading to neutrophil recruitment. This increases ROS and induces NET formation, releasing CTSG that promotes tumor apoptosis via BAX activation.